Latest / This Week In Medicine / 8 18 2025

Transcript

8 18 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in medicine, we will be discussing.
• 0:35
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Co-administered Cougrill and Tide and Semeglu Tide in adults with overweight or obesity.
• 0:44
  [SPEAKER_01]: Background.
• 0:46
  [SPEAKER_01]: Semeglu Tide at a dose of two-point four milligrams has established weight loss and cardiovascular benefits, and Cougrill and Tide at a dose of two-point four milligrams has shown promising results in early phase trials.
• 0:58
  [SPEAKER_01]: The efficacy of the combination known as Kegri Sama, on weight loss in persons with either overweight and co-existing conditions or obesity is unknown.
• 1:07
  [SPEAKER_01]: Conclusions.
• 1:08
  [SPEAKER_01]: Kegrilintide semiglutide provided significant and clinically relevant body weight reductions in adults with overweight or obesity, as compared with placebo.
• 1:18
  [SPEAKER_01]: Next article.
• 1:19
  [SPEAKER_01]: Kegrilintide semiglutide in adults with overweight or obesity and type two diabetes.
• 1:25
  [SPEAKER_01]: Background.
• 1:26
  [SPEAKER_01]: Cogrilintide and semiglutide have each been shown to induce weight loss as monotherapies.
• 1:32
  [SPEAKER_01]: Data are needed on the co-administration of Cogrilintide and semiglutide, called Cogree Sama, for weight management and adults with type II diabetes, including those in a subgroup who are undergoing continuous glucose monitoring conclusions.
• 1:47
  [SPEAKER_01]: Once weekly cagrillion tied semiglu tied, at a dose of two point four milligrams each, resulted in a significantly lower body weight than placebo in adults with obesity and type two diabetes.
• 1:58
  [SPEAKER_01]: Next article.
• 1:59
  [SPEAKER_01]: Across over trial of hospital-wide-latated ringer solution versus normal saline.
• 2:05
  [SPEAKER_01]: Background
• 2:06
  [SPEAKER_01]: Whether lactated ringer's solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain, conclusions.
• 2:15
  [SPEAKER_01]: A hospital-wide policy to administer lactated ringer's solution, rather than normal saline, did not result in a significantly lower incidence of death or readmission to the hospital within ninety days after the index admission.
• 2:34
  [SPEAKER_01]: Next we will be discussing articles from Journal of American Medical Association.
• 2:52
  [SPEAKER_01]: In this randomized clinical trial that included two-hundred adults completing therapy for complicated SORIA's Bacteremia, the probability of a more desirable outcome at day-seventy with Dalbavancin versus Standard Therapy was forty-seven-point-seven percent, which did not achieve the pre-specified criterion for superiority.
• 3:11
  [SPEAKER_01]: Meaning among participants with complicated S-Orius Bacteremia, who achieved blood-culture clearance, D'Alba Vanson was not superior to standard therapy for achieving a more desirable outcome at day seventy.
• 3:28
  [SPEAKER_01]: Next we will be discussing articles from Annals of Internal Medicine.
• 3:32
  [SPEAKER_01]: Geographic variation in receipt of care by specialized oncologists.
• 3:37
  [SPEAKER_01]: Background The growing complexity of cancer care may be driving an increase in subspecialized medical oncologists, who focus on treating specific cancer types.
• 3:47
  [SPEAKER_01]: However, little is known about trends in subspecialization among oncologists and differences in utilization of subspecialists' conclusion.
• 3:55
  [SPEAKER_01]: Subspecialization in oncology is increasing, but is unevenly distributed, with growing differences in utilization across income groups and regions.
• 4:10
  [SPEAKER_01]: Next we will be discussing articles from British Medical Journal.
• 4:13
  [SPEAKER_01]: Global, regional, and national characteristics of the main causes of increased disease burden due to the COVID-nineteen pandemic.
• 4:21
  [SPEAKER_01]: Objective.
• 4:22
  [SPEAKER_01]: To quantify and identify the main causes of increased disease burden due to coronavirus disease, COVID-nineteen, pandemic conclusion.
• 4:32
  [SPEAKER_01]: The COVID-nineteen pandemic significantly increased the burden of several non-COVID conditions, particularly mental health disorders, malaria and young children in the African region, and stroke and ischemic heart disease and older adults, with notable disparities across age and sex.
• 4:48
  [SPEAKER_01]: These findings underscore the urgent need to strengthen health system resilience, enhance integrated surveillance, and adopt syndemic informed strategies to support equitable preparedness for future public health emergencies.
• 5:07
  [SPEAKER_01]: Next we will be discussing articles from Lancet.
• 5:10
  [SPEAKER_01]: Extending the duration of endocrine treatment for early breast cancer, patient-level meta-analysis of twelve randomized trials of aromatase inhibitors in twenty-two-o-three-one post-menopausal women, already treated with at least five years of endocrine therapy.
• 5:25
  [SPEAKER_01]: Background In post-menopausal women with estrogen receptor positive early breast cancer,
• 5:31
  [SPEAKER_01]: Five years of adjuvant to Moxafon substantially reduces fifteen-year recurrence and mortality, aromatis inhibitor treatment, AIT, is even more effective.
• 5:41
  [SPEAKER_01]: We assess the effects of further aid among women recurrence free after at least five years of endocrine therapy type interpretation.
• 5:48
  [SPEAKER_01]: Allocation to five further years of eight reduced subsequent distant recurrence rates by about a quarter, despite substantial non-adherence, longer follow-up would have been needed to help assess directly any effects on mortality.
• 6:07
  [SPEAKER_01]: Next we will be discussing articles in the field of hematology.
• 6:11
  [SPEAKER_01]: Here are the articles from JAMA oncology.
• 6:14
  [SPEAKER_01]: Integrating quality of life and survival in systemic therapy for advanced hepatocelular carcinoma network meta analysis.
• 6:21
  [SPEAKER_01]: Question among available first-line systemic therapy options for unresectable or advanced hepatocelular carcinoma, which treatment provides the optimal balance between overall survival benefit and preservation of health-related quality of life.
• 6:35
  [SPEAKER_01]: Findings.
• 6:36
  [SPEAKER_01]: In this network meta-analysis of nine phase three randomized clinical trials, including six thousand four hundred twenty-five patients, a Tesalismab plus Bevassismab, showed the highest probability of reducing deterioration in most quality of life domains, global health status eighty-five percent, abdominal swelling ninety-five percent, abdominal swelling ninety-five percent.
• 6:59
  [SPEAKER_01]: John does eighty-nine percent, pain eighty-six percent, whereas Tisolitsumab ranked highest for physical functioning, ninety-six percent and fatigue, when integrating quality of life with overall survival, a Tisolitsumab plus bevicesumab significantly outperformed all other treatments across all assessed domains, meaning these findings indicate that a Tisolitsumab plus bevicesumab
• 7:22
  [SPEAKER_01]: provides the optimal balance between survival benefit and preservation of quality of life, compared to other first-line systemic therapy options, in unreceptable or advanced hepaticellular carcinoma, offering a more patient-centered approach for treatment selection.
• 7:43
  [SPEAKER_01]: Next we will be discussing articles in the field of gastroenterology.
• 7:47
  [SPEAKER_01]: Here are the articles from clinical gastroenterology.
• 7:51
  [SPEAKER_01]: Non-invasive disease assessment in eocinophilic asophagitis, with fractionated exhaled nitric oxide, blood, and fecal biomarkers.
• 8:00
  [SPEAKER_01]: Background.
• 8:01
  [SPEAKER_01]: Eocinophilic asophagitis O.
• 8:04
  [SPEAKER_01]: is a chronic inflammatory condition of the esophagus triggered by food and arrow allergens.
• 8:09
  [SPEAKER_01]: There is a need for non-invasive biomarkers that reliably detect O in patients with cardinal symptoms and predict treatment response to reduce endoscopic evaluations' conclusions.
• 8:21
  [SPEAKER_01]: Assessment of Fano may have diagnostic value in differentiating patients with active O from non-O patients, but is not a suitable marker for monitoring disease activity.
• 8:31
  [SPEAKER_01]: Serum EDN, ECP, TARC, and AEC levels are emerging as potential candidates for monitoring disease activity in O.
• 8:45
  [SPEAKER_01]: Next we will be discussing articles in the field of infectious diseases.
• 8:49
  [SPEAKER_01]: Here are the articles from clinical infectious diseases.
• 8:53
  [SPEAKER_01]: Safety of triple dose refampin and tuberculosis treatment, a systematic review and meta-analysis.
• 8:59
  [SPEAKER_01]: Background.
• 9:01
  [SPEAKER_01]: Recent studies suggest that triple dose refampin, TDR, greater than or equal to thirty mg slash kg slash d.
• 9:08
  [SPEAKER_01]: Maybe unsafe, we updated a systematic review to investigate the safety and efficacy of TDR conclusions.
• 9:16
  [SPEAKER_01]: Regimens that use TDR were associated with an increase in sovis, raising concerns regarding safety of TDR regimen.
• 9:29
  [SPEAKER_01]: Here are the articles from arthritis and rheumatology.
• 9:32
  [SPEAKER_01]: Here are the articles from Journal of Clinical rheumatology.
• 9:36
  [SPEAKER_01]: Validation of the Anchossociated Vascularitis Patient reported outcomes questionnaire in a Latin American Vascularis cohort.
• 9:43
  [SPEAKER_01]: Background slash objectives.
• 9:46
  [SPEAKER_01]: The aim of this work is to validate the Anki Associated Vascular Dispatient Reported Outcome.
• 9:51
  [SPEAKER_01]: Off Pro questionnaire in a Latin American Peru, off cohort.
• 9:55
  [SPEAKER_01]: Conclusions.
• 9:57
  [SPEAKER_01]: The Spanish version of the off pro questionnaire correlated with the SF-Thirty Six in off patients from a Peruvian cohort.
• 10:04
  [SPEAKER_01]: These findings may support the use of this instrument in other Latin American populations.
• 10:14
  [SPEAKER_01]: Next we will be discussing articles in the field of cardiology.
• 10:18
  [SPEAKER_01]: Here are the articles from circulation.
• 10:20
  [SPEAKER_01]: Association of Smoking Cannabis with cardiovascular events among veterans, with coronary artery disease.
• 10:27
  [SPEAKER_01]: Background.
• 10:29
  [SPEAKER_01]: Weather cannabis is a risk factor for cardiovascular events is unknown.
• 10:33
  [SPEAKER_01]: We examined the association between smoking cannabis and cardiovascular events in a cohort of older veterans, sixty-six to sixty-eight years of age, with coronary artery disease.
• 10:44
  [SPEAKER_01]: In this cohort of older veterans with coronary artery disease, self-reported cannabis use was not independently associated with increased cardiovascular events over a mean of three point three years of follow-up.
• 11:02
  [SPEAKER_01]: Here are the articles from journals of the American College of Cardiology.
• 11:06
  [SPEAKER_01]: Recurrent events analysis of Master Dept, total ischemic and bleeding events after abbreviated versus prolonged Dept in HBR patients.
• 11:15
  [SPEAKER_01]: Background The effect of dual anti-platelet therapy, DAPT, duration on total events in patients at high bleeding risk, HBR, after percutaneous coronary intervention, PCI, is unclear.
• 11:30
  [SPEAKER_01]: A one-month data duration was associated with similar total naces and masses and reduced total bleeding risk compared with prolonged adapt.
• 11:37
  [SPEAKER_01]: Providing a more comprehensive assessment of the total clinical burden, these findings support the use of an abbreviated duration of adapt after PCI in HBR patients.
• 11:53
  [SPEAKER_01]: from jamma cardiology.
• 11:55
  [SPEAKER_01]: Early childhood food insecurity and cardiovascular health in young adulthood.
• 11:59
  [SPEAKER_01]: Question is food insecurity in early childhood associated with worse cardiovascular health in young adulthood?
• 12:06
  [SPEAKER_01]: Findings.
• 12:07
  [SPEAKER_01]: In this cohort study of one thousand seventy-one children followed up to young adulthood, food insecurity in early childhood was associated with worse cardiovascular health among young adults associated primarily with a higher body mass index.
• 12:21
  [SPEAKER_01]: Supplemental nutrition assistance program participation was associated with mitigation of the association of childhood food insecurity, with cardiovascular health in young adulthood, meaning this study suggests that early childhood food insecurity, especially among children who did not participate in the supplemental nutrition assistance program, may be associated with worse cardiovascular health in young adulthood.
• 12:50
  [SPEAKER_01]: Next we will be discussing articles in the field of endocrinology.
• 12:54
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 12:59
  [SPEAKER_01]: Trends in osteoporosis drug therapy receipt among commercial and Medicare Advantage in Roles and the United States, twenty-eleven to twenty-twenty-two.
• 13:08
  [SPEAKER_01]: Context.
• 13:09
  [SPEAKER_01]: A national assessment of osteoporosis drug therapy, ODT,
• 13:13
  [SPEAKER_01]: Use can in form the extent of under diagnosis and under treatment of osteoporosis objective.
• 13:19
  [SPEAKER_01]: The aim was to describe trends in OTT use by age, sex, fragility fracture, and documented osteoporosis, conclusion.
• 13:29
  [SPEAKER_01]: OTT use for patients with documented osteoporosis has increased but remains low.
• 13:34
  [SPEAKER_01]: Low rates of OTT use for patients with fragility fractures in the absence of documented osteoporosis suggests that under diagnosis of osteoporosis contributes to under use of OTTs.
• 13:52
  [SPEAKER_01]: Here are the articles from diabetes care.
• 13:54
  [SPEAKER_01]: Lack of validity of the glucose management indicator in type one diabetes and pregnancy.
• 14:00
  [SPEAKER_01]: Objective.
• 14:01
  [SPEAKER_01]: The glucose management indicator, GMI, is widely used as a replacement for HBA-one C, but information in pregnancy is very limited.
• 14:10
  [SPEAKER_01]: We assessed the accuracy of GMI and associations with pregnancy outcomes in type one diabetes.C inclusions.
• 14:18
  [SPEAKER_01]: GMI is not an accurate replacement for Heaven One Sea in pregnancy and women with Type One Diabetes.
• 14:30
  [SPEAKER_01]: Next we will be discussing articles in the field of neurology.
• 14:33
  [SPEAKER_01]: Here are the articles from neurology.
• 14:36
  [SPEAKER_01]: Real-world evidence of Brexpiprazole use and six-month mortality, hospitalization, and emergency department visits among persons with dementia.
• 14:45
  [SPEAKER_01]: Background and objectives
• 14:47
  [SPEAKER_01]: Alzheimer disease and other dementia are accompanied by depression and agitation and other behavioral and neuropsychiatric symptoms.
• 14:55
  [SPEAKER_01]: In twenty twenty three, Brex Puprosol became the first anti-cycotic approved by the US Food and Drug Administration to treat agitation and persons with Alzheimer disease.
• 15:05
  [SPEAKER_01]: But like all a typical anti-cycotics, it includes a black box warning of an increased risk of mortality among persons with dementia.
• 15:13
  [SPEAKER_01]: This study provides real-world evidence of mortality in a heterogeneous sample of Brex Piprasal users to understand effects in the population.discussion.
• 15:22
  [SPEAKER_01]: Brex Piprasal use is not associated with differential mortality risk compared with aeropiprasal use among PLWD.
• 15:30
  [SPEAKER_01]: Brex Piprasal offers a treatment option which is important given the heterogeneity of effects of anti-cycotics on persons.
• 15:37
  [SPEAKER_01]: A two-stage least squares method is used to eliminate bias on estimates.
• 15:42
  [SPEAKER_01]: Because of observed and unobserved differences between the two groups, but the small sample size is a limitation.
• 15:54
  [SPEAKER_01]: Next we will be discussing articles in the field of pulmonary and critical care.
• 15:59
  [SPEAKER_01]: Here are the articles from chest.
• 16:01
  [SPEAKER_01]: Continuous glucose monitoring for hyperglycemia in critically ill patients.
• 16:06
  [SPEAKER_01]: A randomized controlled trial.
• 16:08
  [SPEAKER_01]: Background.
• 16:10
  [SPEAKER_01]: Continuous glucose monitors, CGMs, could potentially improve management of hyperglycemia compared with standard point of care glucose monitoring for critically ill patients.
• 16:20
  [SPEAKER_01]: However, there is limited evidence to support routine use of CGMs in the ICU research question.
• 16:27
  [SPEAKER_01]: In critically ill patients with hyperglycemia, do CGMs improve time within target glucose range compared with standard of care, interpretation.
• 16:36
  [SPEAKER_01]: The results of this study do not support CGMs as a superior method for routine glucose monitoring in the ICU compared with standard of care.
• 16:51
  [SPEAKER_01]: Here are the articles from the American Journal of Respiratory and Critical Care Medicine.
• 16:55
  [SPEAKER_01]: Endotypes of pseudomonas aruginocia infection in bronchiectasis are associated with inhaled antibiotic response.
• 17:02
  [SPEAKER_01]: Results from two randomized, double-blind, placebo-controlled phase-three trials, OR-bit-three, and OR-bit-four rationale.
• 17:10
  [SPEAKER_01]: Replicate phase-three trials of inhaled antibiotics and patients with bronchiectasis
• 17:15
  [SPEAKER_01]: have produced inconsistent results, objectives.
• 17:18
  [SPEAKER_01]: This study investigated if different microbial and inflammatory endotypes are linked to antibiotic response in patients with chronic pseudomonas aruginocia infection.
• 17:28
  [SPEAKER_01]: Conclusions.
• 17:29
  [SPEAKER_01]: Patients with chronic P-aruginocia have heterogeneous microbiota and inflammatory profiles.
• 17:35
  [SPEAKER_01]: Influencing antibiotic treatment responses in bronchiectuses, future trials could be improved by patient stratification, including accounting for geographical differences and biomarkers to represent microbiota differences.
• 17:53
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 17:57
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 18:01
  [SPEAKER_01]: Core outcome measure for life participation in patients with CKD, standardized outcomes in a phrology workshop support.
• 18:09
  [SPEAKER_01]: Patience, caregivers, and health professionals support the use of standardized outcomes in a phrology, life participation as the core outcome measure for life participation in patients with CKD.
• 18:21
  [SPEAKER_01]: Further work is needed to pilot and validate the standardized outcomes in a phrology.
• 18:25
  [SPEAKER_01]: Life participation measure in patients with CKD before the need for KRT.
• 18:30
  [SPEAKER_01]: A core outcome measure will support consistent reporting of life participation in trials in patients with CKD.
• 18:37
  [SPEAKER_01]: Next article.
• 18:38
  [SPEAKER_01]: Frailty in adults with CKD and validation of the kidney failure risk equation in frailty subgroups.
• 18:45
  [SPEAKER_01]: The four variable kidney failure risk equation, KFRE, does not accurately estimate kidney failure risk in frail individuals.
• 18:52
  [SPEAKER_01]: Prognostication of kidney failure is improved in frail individuals with CKD by replacing EGFR creatinine with SISTAT and C-based EGFRE in the KFRE model.
• 19:04
  [SPEAKER_01]: Consideration of competing mortality risk is particularly important in those with frailty and higher KFRE risk predictions.
• 19:18
  [SPEAKER_01]: Here are the articles from kidney international reports.
• 19:21
  [SPEAKER_01]: A systematic review of treatment for acute interstitial nephritis.
• 19:25
  [SPEAKER_01]: Introduction.
• 19:26
  [SPEAKER_01]: Acute interstitial nephritis, AIN, is a common cause of acute kidney injury.
• 19:32
  [SPEAKER_01]: It is characterized by tubular inflammation with eocinophils histologically.
• 19:36
  [SPEAKER_01]: The main state treatment for AIN includes early diagnosis, underlying infection or systemic disease treatment.
• 19:43
  [SPEAKER_01]: cessation of the offending agent and corticosteroid therapy when indicated.
• 19:48
  [SPEAKER_01]: This systematic review aims to evaluate the efficacy and safety of pharmacotherapy treatments for AIN by assessing treatment outcomes and adverse effects taught's conclusion.
• 19:58
  [SPEAKER_01]: Consistent evidence supporting the use of corticosteroids for treating aim needs to be more comprehensive.
• 20:04
  [SPEAKER_01]: There needs to be a clear consensus on the optimal treatment regimen.
• 20:08
  [SPEAKER_01]: High-quality randomized controlled trials are required to help establish evidence-based guidelines for treating aim.
• 20:15
  [SPEAKER_01]: Next article.
• 20:16
  [SPEAKER_01]: Double ICodextron dose randomized controlled trial of a double ICodextron dose for older patients on incremental continuous ambulatory peritoneal dialysis.
• 20:26
  [SPEAKER_01]: Introduction
• 20:27
  [SPEAKER_01]: Icodextran enhances ultra-filtration, UF, in patients on peritoneal dialysis, PD, but is restricted to one bag slash D, according to regulatory authorities.
• 20:38
  [SPEAKER_01]: The double Icodextran dose, Dido, study, is a prospective randomized trial investigating the superiority and safety of using two bags slash D versus one bag slash D of Icodextran.
• 20:52
  [SPEAKER_01]: To extend incremental, three bags slash D, continuous ambulatory PD, CAPD, duration in older incident patients' conclusion.
• 21:02
  [SPEAKER_01]: In older patients on incremental CAPD, the double-icodextrindoose did not reduce the primary outcome incidents compared with the single-icodextrindoose.
• 21:11
  [SPEAKER_01]: Significantly enhanced UF was observed in the double-icodextrin dose group, and no safety issue was identified.
• 21:18
  [SPEAKER_00]: Thank you for listening to this week in medicine.
• 21:20
  [SPEAKER_00]: Your filtered medical journal summary.
• 21:22
  [SPEAKER_00]: Have a great week ahead.
• 21:24
  [SPEAKER_00]: Stay blessed and be humane.